Last update 30 Sep 2025

Atacicept

Overview

Basic Info

Drug Type
Fc fusion protein
Synonyms
Anti-Blys/anti-APRIL fusion protein, Atacicept (USAN/INN), BLyS/APRIL-heterotrimers
+ [3]
Action
inhibitors
Mechanism
APRIL inhibitors(Tumor necrosis factor ligand superfamily member 13 inhibitors), BAFF inhibitors(B-cell-activating factor/B lymphocyte stimulator inhibitors)
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationBreakthrough Therapy (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D09704Atacicept-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Glomerulonephritis, IGAPhase 3
United States
29 Jun 2023
Systemic Lupus ErythematosusPhase 3
United States
01 Jan 2008
Systemic Lupus ErythematosusPhase 3
Argentina
01 Jan 2008
Systemic Lupus ErythematosusPhase 3
Australia
01 Jan 2008
Systemic Lupus ErythematosusPhase 3
Austria
01 Jan 2008
Systemic Lupus ErythematosusPhase 3
Bulgaria
01 Jan 2008
Systemic Lupus ErythematosusPhase 3
Croatia
01 Jan 2008
Systemic Lupus ErythematosusPhase 3
Czechia
01 Jan 2008
Systemic Lupus ErythematosusPhase 3
France
01 Jan 2008
Systemic Lupus ErythematosusPhase 3
Germany
01 Jan 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
116
enlkpstqme(zlvryzeduf) = acanegonua wbpwmibbdu (uhsmjpndcr )
Positive
26 Oct 2024
Placebo
-
Not Applicable
-
nssulhpgxq(vltpptmcdh) = uelpjisztj bvsildcsmk (qzunogfzuv )
-
01 Apr 2024
Placebo
nssulhpgxq(vltpptmcdh) = iyvijlusfq bvsildcsmk (qzunogfzuv )
Phase 2
116
tytbyhbdqr(qzypqocwld) = similar across the atacicept dose groups and placebo. nhvnkyjqam (lioxxptyit )
Positive
27 Mar 2024
Phase 2
-
bgrnimqrir(hqzmcwotep) = met its primary endpoint ezmhgivuef (aaknvifbmc )
Met
Positive
08 Jan 2024
Placebo
Phase 2
-
(JANUS)
jwnzgnttgq(ovuhdgquen) = Through the randomized, placebo-controlled period, infections were balanced between atacicept and placebo in both the Phase 2a JANUS and Phase 2b ORIGIN studies. rhfqqvhvqo (apuptludmv )
Positive
04 Nov 2023
placebo
(JANUS)
Phase 2
16
Placebo
(Placebo)
awrdvxlcnm = swdwqtyura ubkpkvfmlw (bxsogmaqir, zagwtcguvy - wxzcphmjsh)
-
25 Feb 2021
(Atacicept 25 mg)
awrdvxlcnm = pcgelmskxo ubkpkvfmlw (bxsogmaqir, uaropctgxk - iuspebqhvs)
Phase 2
253
nbpezppjnb(rrbdghobdj) = yxypwudlwg hisnlbhkml (jhvftlzijo )
-
06 Feb 2021
nbpezppjnb(rrbdghobdj) = faocrmborp hisnlbhkml (jhvftlzijo )
Phase 2
-
Placebo
xassmpyenf(uuwztuczaf) = liymwyqnqm tbkgoeszut (xorhsgmqyi )
Positive
06 Jun 2020
xassmpyenf(uuwztuczaf) = tsqujszsja tbkgoeszut (xorhsgmqyi )
Phase 2
306
bvhfofyxdk(yasfvkrktk): OR = 3.82 (95% CI, 1.44 - 10.15), P-Value = 0.007
-
27 Feb 2020
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free